Effect of subcutaneous methylnaltrexone on patient-reported constipation symptoms

Value in Health

Volumn 14, Issue 1, 2011, Pages 177-183

  Iyer, Shrividya S ^a   Randazzo, Bruce P ^a   Tzanis, Evan L ^a   Schulman, Seth L ^a   Zhang, Haiying ^a   Wang, Wenjin ^a   Manley, Amy L ^a  

^a PFIZER INC   (United States)

Author keywords

Chronic nonmalignant pain; Constipation symptoms; Methylnaltrexone; Opioid induced constipation; Pain scores; Patient reported outcomes

Indexed keywords

17 METHYLNALTREXONE; OPIATE; PLACEBO; DRUG DERIVATIVE; NALTREXONE; NARCOTIC ANALGESIC AGENT; NARCOTIC ANTAGONIST; QUATERNARY AMMONIUM DERIVATIVE;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ADULT; ARTICLE; BACKACHE; CHRONIC PAIN; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FECES ANALYSIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; PAIN ASSESSMENT; PATIENT ASSESSMENT; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SYMPTOM; TREATMENT DURATION; CHEMICALLY INDUCED DISORDER; CHRONIC DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; MIDDLE AGED; SUBCUTANEOUS DRUG ADMINISTRATION;

ANALGESICS, OPIOID; BACK PAIN; CHRONIC DISEASE; CONSTIPATION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; NALTREXONE; NARCOTIC ANTAGONISTS; QUATERNARY AMMONIUM COMPOUNDS;

EID: 79952690239     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2010.11.003     Document Type: Article

References (31)

1. Staats PS, Markowitz J, Schein J. Incidence of constipation associated with long-acting opioid therapy: a comparative study. South Med J 2004;97:129-34. (Pubitemid 38222814)
2. Pappagallo M. Incidence, prevalence and management of opioid bowel dysfunction. Am J Surg 2001;182(Suppl.):11S-18S. (Pubitemid 34072942)
3. Schug SA, Garrett WR, Gillespie G. Opioid and non-opioid analgesics. Best Pract Res Clin Anaesthesiol 2003;17:91-110. (Pubitemid 38950015)
4. Thorpe DW. Management of opioid induced constipation. Curr Pain Headache Rep 2001;5:237-40.
5. Gutstein HB, Akil H. Opioid analgesics. in: Hardman JG, Limbird LE, Gilman AG, eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics. New York: McGraw-Hill Medical Publishing Division; 2001.
6. De Luca A, Coupar IM. Insights into opioid action in the intestinal tract. Pharmacol Ther 1996;69:103-15. (Pubitemid 26111425)
7. Thomas J, Karver S, Cooney GA, et al. Methylnaltrexone for opioid-induced constipation in advanced illness. N Engl J Med 2008;358:2332-43. (Pubitemid 351749157)
8. ® Pharmaceuticals, Inc, Tarrytown, NY, USA. Available from: www.relistor.com and www.wyeth.com/hcp/relistor/prescribing-information. [Accessed January 22, 2010.]
9. Foss JF. A review of the potential role of methylnaltrexone in opioid bowel dysfunction. Am J Surg 2001;281(5 A Suppl.):19S-26S. (Pubitemid 34072943)
10. Brown DR, Goldberg LI. The use of quaternary narcotic antagonists in opiate research. Neuropharmacology 1985;24:181-91. (Pubitemid 15051584)
11. Ho WZ, Guo CJ, Yuan CS, et al. Methylnaltrexone antagonizes opioid-mediated enhancement of HIV infection of human blood mononuclear phagocytes. J Pharmacol Exp Ther 2003:307(3);1158-62.
12. Kurz A, Sessler DI. Opioid-induced bowel dysfunction: pathophysiology and potential new therapies. Drugs 2003;63:649-71. (Pubitemid 36408072)
13. Shaiova L, Rim G, Friedman D, Jahdi M. A review of methylnaltrexone, a peripheral opioid receptor antagonist, and its role in opioid-induced constipation. Palliat Support Care 2007;5:161-6.
14. Blonsky R, Michna E, Schulman S, et al. Subcutaneous methylnaltrexone for the treatment of opioid-induced constipation in patients with chronic non-malignant pain. J Pain 2009;10(Suppl.):S52.
15. Lewis SJ, Heaton KW. Stool form as a useful guide to intestinal transit time. Scand J Gastroenterol 1997;32:920-4. (Pubitemid 27382038)
16. Farrar JT, Young Jr. JP, LaMoreaux L, et al. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 2001;94:149-58. (Pubitemid 33016608)
17. Frank L, Kleinman L, Farup C, et al. Psychometric validation of a constipation symptom assessment questionnaire. Scand J Gastroenterol 1999;34:870-7. (Pubitemid 29470564)
18. Slappendel R, Simpson K, Dubois D, Keininger D. Validation of the PAC-SYM questionnaire for opioid induced constipation in patients with chronic low back pain. Eur J Pain 2006;10:209-17. (Pubitemid 43255207)
19. Portenoy RK. Opioid therapy for chronic nonmalignant pain: a review of the critical issues. J Pain Symptom Manage 1996;11:203-17. (Pubitemid 26102522)
20. Bell TJ, Panchal SJ, Miaskowski C, et al. The prevalence, severity, and impact of opioid-induced bowel dysfunction: results of a US and European survey (PROBE 1). Pain Med 2008;10:35-42.
21. Culpepper-Morgan JA, Inturrisi CE, Portenoy RK, et al. Treatment of opioid-induced constipation with oral naloxone: a pilot study. Clin Pharmacol Ther 1992;52:90-5.
22. Portenoy RK, Thomas J, Moehl Boatwright ML, et al. Subcutaneous methylnaltrexone for the treatment of opioid-induced constipation in patients with advanced illness: a double-blind, randomized, parallel group, doseranging study. J Pain Symptom Manage 2008;35:458-68. (Pubitemid 351601995)
23. Lembo A, Camilleri M. Chronic constipation. N Engl J Med 2003;349:1360-8.
24. Camilleri M, Kerstens R, Rykx A, Vandeplassche L. A placebo-controlled trial of prucalopride for severe chronic constipation. N Engl J Med 2008;358:2344-54. (Pubitemid 351749158)
25. McShane RE, McLane AM. Constipation: consensual and empirical validation. Nurs Clin North Am 1985;20:801-8.
26. De Schepper HU, Cremonini F, Park MI, Camilleri M. Opioids and the gut: pharmacology and current clinical experience. Neurogastroenterol Motil 2004;16:383-94. (Pubitemid 39140632)
27. McMillan SC. Assessing and managing opiate-induced constipation in adults with cancer. Cancer Control 2004;11(Suppl.):3S-9S.
28. Yuan CS, Foss JF, O'Connor M, et al. Methylnaltrexone for reversal of constipation due to chronic methadone use. JAMA 2000;283:367-72. (Pubitemid 30051755)
29. Di Palma JA, Cleveland MvB, McGowan J, Herrera JL. A randomized, multicenter comparison of polyethylene glycol laxative and tegaserod in treatment of patients with chronic constipation. Am J Gastroenterol 2007;102:1964-71. (Pubitemid 47301532)
30. Becker G, Galandi D, Blum HE. Peripherally acting opioid antagonists in the treatment of opiate-related constipation: a systematic review. J Pain Symptom Manage 2007:34: 547-65. (Pubitemid 350001379)
31. Chamberlain B, Cross K, Winston J, et al. Methylnaltrexone treatment of opioid induced constipation in patients with advanced illness. J Pain Symptom Manage 2009. Available from: http://dx.doi.org/10.1016/j.jpainsymman. 2009.02.234.